



(11)

EP 3 242 888 B8

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 54

(48) Corrigendum issued on:
02.06.2021 Bulletin 2021/22

(45) Date of publication and mention
of the grant of the patent:
25.11.2020 Bulletin 2020/48

(21) Application number: **16716673.5**

(22) Date of filing: **07.01.2016**

(51) Int Cl.:
C07K 14/71 ^(2006.01) **A61K 38/17** ^(2006.01)
A61P 19/08 ^(2006.01)

(86) International application number:
PCT/IB2016/000403

(87) International publication number:
WO 2016/110786 (14.07.2016 Gazette 2016/28)

(54) **SOLUBLE FGFR3 DECOYS FOR TREATING SKELETAL GROWTH DISORDERS**
LÖSLICHE FGFR3-KÖDER ZUR BEHANDLUNG VON WACHSTUMSSTÖRUNGEN
LEURRES FGFR3 SOLUBLES POUR LE TRAITEMENT DE TROUBLES DE LA CROISSANCE
OSSEUSE

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

(30) Priority: **07.01.2015 EP 15290003**

(43) Date of publication of application:
15.11.2017 Bulletin 2017/46

(60) Divisional application:
20202446.9 / 3 828 198

(73) Proprietors:
• **Pfizer Inc.**
New York, NY 10017 (US)
• **INSERM - Institut National de la Santé et de la**
Recherche Médicale
75013 Paris (FR)
• **Université Côte d'Azur**
06100 Nice Cedex 2 (FR)

(72) Inventors:
• **GOUZE, Elvire**
06410 Biot (FR)

• **GARCIA, Stéphanie**
06200 Nice (FR)

(74) Representative: **Zwicker, Jörk**
ZSP Patentanwälte PartG mbB
Hansastraße 32
80686 München (DE)

(56) References cited:
WO-A1-2014/111467 WO-A2-2007/014123
WO-A2-2008/133873 WO-A2-2011/084711
US-A1- 2003 235 589

• **S. GARCIA ET AL: "Postnatal Soluble FGFR3**
Therapy Rescues Achondroplasia Symptoms
and Restores Bone Growth in Mice", SCIENCE
TRANSLATIONAL MEDICINE, vol. 5, no. 203, 18
September 2013 (2013-09-18), XP055194295,
ISSN: 1946-6234, DOI:
10.1126/scitranslmed.3006247 cited in the
application

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- F. H. CHEN ET AL: "Interaction of Cartilage Oligomeric Matrix Protein/Thrombospondin 5 with Aggrecan", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 282, no. 34, 22 June 2007 (2007-06-22), pages 24591-24598, XP055194302, ISSN: 0021-9258, DOI: 10.1074/jbc.M611390200
- D LI ET AL: "A novel decoy receptor fusion protein for FGF-2 potently inhibits tumour growth", BRITISH JOURNAL OF CANCER, vol. 111, no. 1, 29 May 2014 (2014-05-29), pages 68-77, XP055160715, ISSN: 0007-0920, DOI: 10.1038/bjc.2014.282
- SU-JEONG HWANG ET AL: "High-level Expression and Purification of a Designed Angiopoietin-1 Chimeric Protein, COMP-Ang1, Produced in Chinese Hamster Ovary Cells", JOURNAL OF PROTEIN CHEMISTRY, KLUWER ACADEMIC PUBLISHERS-PLENUM PUBLISHERS, NE, vol. 27, no. 5, 9 May 2008 (2008-05-09), pages 319-326, XP019609300, ISSN: 1573-4943

Remarks:

The file contains technical information submitted after the application was filed and not included in this specification